Publications by authors named "Lauri Veijalainen"
Article Synopsis
- Mepolizumab, a treatment for severe eosinophilic asthma, provides clinical benefits, but real-world data in Finland were previously lacking.
- This study reviewed the records of 51 patients who started mepolizumab between 2016 and 2019, tracking various health outcomes over up to 24 months.
- Results showed significant reductions in eosinophil count, asthma exacerbations, and corticosteroid use, along with improvements in quality of life, aligning with findings from randomized clinical trials.
Purpose: The burden associated with chronic obstructive pulmonary disease (COPD) is substantial. The objectives of this study were to describe healthcare resource utilization (HCRU) and HCRU-associated costs in patients with COPD in Finland, according to disease severity and blood eosinophil count (BEC).
Patients And Methods: This non-interventional, retrospective registry study (GSK ID: HO-17-17558) utilized data from the specialist care hospital register.